Migraine – Landscape & Forecast – Disease Landscape & Forecast

Migraine, which afflicts approximately 72 million people in the major pharmaceutical markets according to Clarivate epidemiology, is a heterogeneous condition requiring individualized treatment based largely on a patient’s symptoms and needs, headache pattern, comorbidities, contraindications, and treatment history. With the launch of newer migraine-specific treatment alternatives (e.g., anti-CGRP MAbs for migraine prevention, oral CGRP receptor antagonists for both the treatment of acute migraine attacks and migraine prevention) and a range of innovative reformulations set for near-term launch in the United States, brand choice is rapidly expanding in this heavily generic market. Understanding the intersecting forces of unmet need, cost / coverage, and the headwinds posed by low-cost, early-line SOCs will be key to the success of current and future players in migraine.

Questions Answered:

  • What events will shape the future of the acute / preventive and episodic / chronic market segments?
  • How are the anti-CGRP MAbs (e.g., Aimovig, Emgality) and oral gepants (i.e., Nurtec ODT, Qulitpa) being integrated into the generic-dominant migraine prophylaxis market? Which brands will be the most competitive and why?
  • What is the dynamic between Ubrelvy and Nurtec ODT? How are oral gepants being adopted into the triptan-dominant acute segment?
  • How will novel reformulations compete for patient share with existing options in the niche segment of patients who need non-oral alternatives?

Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.

Primary research: Approximately 20 country-specific interviews with thought-leading neurologists, supported by survey data collected for this content and other Clarivate research.

Epidemiology: Total, diagnosed, and drug-treated prevalent cases of episodic and chronic migraine, segmented by acute and prophylactic treatment.

Emerging therapies: Phase II: 6 drugs; Phase III / preregistration: 5 drugs.

Market forecast features: Patient-based market forecast extending through 2030, segmented by brands and generics.

Product Description:

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Solution Enhancement:

Disease Landscape & Forecast will feature continuous updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold.

Table of contents

  • Migraine - Landscape & Forecast - Disease Landscape & Forecast
    • Key Updates
      • Q2 2022
        • April 2022
      • Q1 2022
        • March 2022
        • February 2022
        • January 2022
      • Q4 2021
        • December 2021
        • November 2021
      • Q3 2021
        • September 2021
        • August 2021
        • July 2021
      • Q2 2021
        • June 2021
        • May 2021
        • April 2021
    • Key Findings
      • Migraine - Key Findings - March 2022
        • June 2021
        • May 2021
        • April 2021
    • Market Outlook
      • Key Findings
        • Market Share of Drug Classes for the Acute Treatment of Migraine in 2020
        • Market Share of Drug Classes for the Acute Treatment of Migraine in 2030
        • Market Share of Drug Classes for the Prophylactic Treatment of Migraine in 2020
        • Market Share of Drug Classes for the Prophylactic Treatment of Migraine in 2030
        • Migraine SWOT Analysis
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for Migraine?
        • What Factors Are Constraining the Market for Migraine?
        • Market Share and Treated Patients for Acute Migraine by Country: 2020 and 2030
        • Market Share and Treated Patients for Migraine Prophylaxis by Country: 2020 and 2030
      • Segment-Specific Trends
        • Sales of Acute and Prophylactic Treatments in the Episodic and Chronic Migraine Markets: 2020 and 2030
      • Drug-Class-Specific Trends
        • Major-Market Sales of Key Triptans in Acute Migraine: 2020-2030
        • Major-Market Patient Share of Key Triptans in Acute Migraine: 2020-2030
        • U.S. Sales of Emerging Acute Treatments in Migraine: 2020-2030
        • Anti-CGRP Monoclonal Antibodies
        • CGRP Receptor Antagonists
        • Major-Market Sales of CGRP-Targeted Therapies for Migraine Prophylaxis: 2020-2030
        • Major-Market Patient Share of CGRP-Targeted Therapies for Migraine Prophylaxis in Episodic Migraine: 2020-2030
        • Major-Market Patient Share of CGRP-Targeted Therapies for Migraine Prophylaxis in Chronic Migraine: 2020-2030
        • Major-Market Sales of Other Prophylactic Treatments in Migraine: 2020-2030
        • Major-Market Patient Share of Other Prophylactic Treatments in Migraine: 2020-2030
    • Forecast
      • Market Forecast Assumptions: Acute Migraine
      • Market Forecast Dashboard: Acute Migraine
      • Market Forecast Assumptions: Migraine Prophylaxis
      • Market Forecast Dashboard: Migraine Prophylaxis
    • Etiology and Pathophysiology
      • Disease Overview
        • Anatomy of the Brain
      • Genetic Factors
        • Environmental Factors: Migraine Triggers
          • Select Precipitating (Trigger) Factors Associated with Migraine
        • Key Pathways and Drug Targets
          • Substances Involved in Neurotransmission in Migraine
          • Role of Select 5-HT Receptor Subtypes in Migraine
          • Neurogenic Inflammation in Migraine
          • Neurogenic Inflammation in Migraine Headache
          • Progression of Spreading Depression and Oligemia Believed to Be Associated with Migraine Aura
          • Other Processes Involved in Migraine
      • Epidemiology
        • Key Findings
          • Epidemiology Populations
            • Disease Definition
            • Sources Used for Total Prevalent Cases of Migraine
            • 12-Month Total Migraine Cases in the Major Pharmaceutical Markets: 2020-2030 (thousands)
            • Disease Definition
            • Methods
            • Sources Used for Total Prevalent Cases of Episodic Migraine
            • Total 12-Month Episodic Migraine Cases in the Major Pharmaceutical Markets: 2020-2030 (thousands)
            • Disease Definition
            • Sources Used for Total Prevalent Cases of Chronic Migraine
            • Total 12-Month Chronic Migraine Cases in the Major Pharmaceutical Markets: 2020-2030 (thousands)
            • Disease Definition
            • Methods
            • Sources Used for Frequency of Episodic Migraine Attacks
            • Total 12-Month Episodic Migraine Cases According to Frequency of Attacks in the Major Pharmaceutical Markets: 2020-2030 (thousands)
            • Disease Definition
            • Methods
            • Sources Used for Total Episodic Migraine Events
            • Total 12-Month Episodic Migraine Events in the Major Pharmaceutical Markets: 2020-2030 (thousands)
            • Diagnosed Prevalent Cases of Episodic Migraine: 2020-2030 (thousands)
            • Diagnosed Prevalent Cases of Chronic Migraine: 2020-2030 (thousands)
            • Acute Migraine Treatment
            • Acutely Drug-Treated Prevalent Cases of Episodic Migraine: 2020-2030 (thousands)
            • Acutely Drug-Treated Prevalent Cases of Chronic Migraine: 2020-2030 (thousands)
            • Migraine Prophylaxis
            • Prophylactically Drug-Treated Prevalent Cases of Episodic Migraine: 2020-2030 (thousands)
            • Prophylactically Drug-Treated Prevalent Cases of Chronic Migraine: 2020-2030 (thousands)
        • Current Treatment
          • Key Findings
            • Treatment Goals
              • Key Endpoints Used in Clinical Trials for Migraine
            • Key Current Therapies: Acute Treatment
              • Overview
              • Mechanism of Action of Key Current Drug Classes Used for the Acute Treatment of Migraine
              • Current Treatments Used for the Acute Treatment of Migraine
              • Market Events Impacting the Use of Key Current Acute Therapies in Migraine
              • Advantages and Disadvantages of Sumatriptan
              • Expert Insight: Sumatriptan
              • Advantages and Disadvantages of Treximet
              • Advantages and Disadvantages of Rizatriptan
              • Advantages and Disadvantages of Frovatriptan
              • Advantages and Disadvantages of Zolmitriptan
              • Expert Insight: Zolmitriptan
              • Advantages and Disadvantages of Other Triptans
              • Advantages and Disadvantages of Reyvow
              • Key Results From Select Clinical Trials Investigating Reyvow for the Acute Treatment of Migraine
              • Ongoing Clinical Development of Reyvow
              • Expert Insight: Reyvow
              • Key Results From Select Clinical Trials Investigating Ubrelvy for the Acute Treatment of Migraine
              • Ongoing Clinical Development of Ubrelvy
              • Expert Insight: Ubrelvy
              • Advantages and Disadvantages of Nurtec ODT / Vydura
              • Key Results From Select Clinical Trials Investigating Nurtec ODT / Vydura for the Acute Treatment of Migraine
              • Key Results From Clinical Trials Investigating Nurtec ODT / Vydura for the Prophylactic Treatment of Migraine
              • Ongoing Clinical Development of Nurtec ODT / Vydura
              • Expert Insight: Nurtec ODT / Vydura
              • Dihydroergotamine Mesylate
              • Advantages and Disadvantages of Dihydroergotamine Mesylate
              • Expert Insight: DHE
              • Trudhesa
              • Advantages and Disadvantages of Trudhesa
              • Key Results From Clinical Trials Investigating Trudhesa for the Acute Treatment of Migraine
              • Expert Insight: Trudhesa
              • Advantages and Disadvantages of Elyxyb
              • Key Results From Clinical Trials Investigating Elyxyb for the Acute Treatment of Migraine
              • Expert Insight: Elyxyb
              • Advantages and Disadvantages of Prescription NSAIDs and Nonnarcotic Analgesics
              • Advantages and Disadvantages of Narcotic Prescription Analgesics
            • Key Current Therapies: Prophylactic Treatment
              • Overview
              • Mechanism of Action of Key Current Drug Classes Used for the Prophylactic Treatment of Migraine
              • Current Treatments Used for the Prophylactic Treatment of Migraine
              • Market Events Impacting the Use of Key Current Preventive Therapies in Migraine
              • Advantages and Disadvantages of Topiramate
              • Advantages and Disadvantages of Divalproex
              • Advantages and Disadvantages of Botox
              • Advantages and Disadvantages of Aimovig
              • Key Results From Select Clinical Trials Investigating Aimovig for the Prophylactic Treatment of Migraine
              • Ongoing Clinical Development of Aimovig
              • Expert Insight: Aimovig
              • Advantages and Disadvantages of Ajovy
              • Key Results From Select Clinical Trials Investigating Ajovy for the Prophylactic Treatment of Migraine
              • Ongoing Clinical Development of Ajovy
              • Advantages and Disadvantages of Emgality
              • Key Results From Select Clinical Trials Investigating Emgality for the Treatment of Migraine
              • Ongoing Clinical Development of Emgality
              • Expert Insights: Emgality
              • Advantages and Disadvantages of Vyepti
              • Key Results From Select Clinical Trials Investigating Vyepti for the Treatment of Migraine
              • Ongoing Clinical Development Program of Vyepti
              • Qulipta
              • Advantages and disadvantages of Qulipta
              • Key Results From Clinical Trials Investigating Qulipta for the Prophylactic Treatment of Migraine
              • Ongoing Clinical Development of Qulipta
              • Expert Insight: Qulipta
              • Advantages and Disadvantages of Beta Blockers
              • Advantages and Disadvantages of Amitriptyline
              • Advantages and Disadvantages of Calcium Channel Blockers
            • Medical Practice
              • Overview
              • Factors Influencing Drug Selection in Migraine
              • Treatment Decision Tree for the Acute Treatment of Migraine: United States
              • Treatment Decision Tree for the Prophylactic Treatment of Migraine: United States
              • Treatment Decision Tree for the Acute Treatment of Migraine: Europe
              • Treatment Decision Tree for the Prophylactic Treatment of Migraine: Europe
              • Treatment Decision Tree for the Acute Treatment of Migraine: Japan
              • Treatment Decision Tree for the Prophylactic Treatment of Migraine: Japan
          • Unmet Need Overview
            • Current and Future Attainment of Unmet Needs in Migraine
            • Top Unmet Needs in Migraine: Current and Future Attainment
            • Expert Insight: Unmet Need in Migraine
          • Emerging Therapies
            • Key Findings
              • Key Emerging Therapies
                • Key Therapies in Development for Migraine
                • Estimated Launch Dates of Key Emerging Therapies for the Treatment of Migraine
                • Qtrypta Profile
                • Analysis of Clinical Development Program for Qtrypta
                • Expert Insight: Qtrypta (M-207)
                • Expectations for Launch and Sales Opportunity of Qtrypta (M-207) in Migraine
                • AXS-07
                • AXS-07 Profile
                • Analysis of Clinical Development Program for AXS-07
                • Expert Insight: AXS-07
                • Expectations for Launch and Sales Opportunity of AXS-07 in Migraine
                • STS101
                • STS101 Profile
                • Analysis of Clinical Development Program for STS101
                • Expert Insight: STS101
                • Expectations for Launch and Sales Opportunity of STS101 in Migraine
                • Zavegepant Profile
                • Analysis of Clinical Development Program for Zavegepant
                • Expert Insight: Zavegepant
                • Expectations for Launch and Sales Opportunity of Zavegepant in Migraine
              • Early-Phase Pipeline Analysis
                • Select Compounds in Early-Phase Development for the Acute Treatment of Migraine
                • Select Compounds in Early-Phase Development for the Prophylactic Treatment of Migraine
            • Access & Reimbursement Overview
              • Region-Specific Reimbursement Practices
                • Key Market Access Considerations in Migraine: United States
                • General Reimbursement Environment: United States
                • Key Market Access Considerations in Migraine: EU5
                • General Reimbursement Environment: EU5
                • Key Market Access Considerations in Migraine: Japan
                • General Reimbursement Environment: Japan
            • Appendix
              • Migraine Bibliography

          Login to access report